首页> 外文期刊>Ophthalmic Research: Journal for Research in Experimental and Clinical Ophthalmology >Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy.
【24h】

Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy.

机译:白细胞介素8,一氧化氮和谷胱甘肽在增生性玻璃体视网膜病变和增生性糖尿病视网膜病变中的状态。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate interleukin-8 (IL-8), nitric oxide (NO) and glutathione (GSH) profiles in vitreous humor and blood samples in patients with proliferative diabetic retinopathy (PDR) and in patients with proliferative vitreoretinopathy (PVR) and to compare the levels with those of controls. PATIENTS AND METHODS: NO concentrations were determined by using the Greiss reaction in plasma and vitreous humor samples. GSH levels were determined in both blood and vitreous humor samples, using DTNB, a disulfide chromogen. Vitreous IL-8 were assayed by ELISA. Twenty-three patients with PDR, 18 patients with PVR and 21 cadavers as the control group were included in the study. RESULTS: Plasma and vitreous NO levels were found to be 25.6 +/- 2.1 and 36.9 +/- 3.0 micromol/l in patients with PDR, 27.0 +/- 4.7 and 34.3 +/- 2.9 micromol/l in patients with PVR and 17.4 +/- 2.7 and 15.9 +/- 1.4 micromol/l in controls, respectively. Vitreous humor and plasma NO levels did not show any statistically significant difference between PDR and PVR groups. However, the values for vitreous in both groups were significantly higher than those of controls (p < 0.0001). Although IL-8 levels in vitreous samples of patients with PDR were not significantly different (79.6 +/- 9.7 pg/ml) from those of patients with PVR (42.2 +/- 7.3 pg/ml) (p = 0.06), the levels in both groups were significantly higher than those of controls (19.0 +/- 3.9 pg/ml) (p < 0.0001 and p < 0.05, respectively). Blood and vitreous GSH levels were found to be 5.3 +/- 0.4 micromol/g. Hb and 0.58 +/- 0.16 micromol/l in patients with PDR and 8.4 +/- 0.5 micromol/g. Hb and 15.7 +/- 2.2 micromol/l in patients with PVR and 12.0 +/- 1.1 micromol/g. Hb and 0.26 +/- 0.03 mmol/l in controls, respectively. Vitreous and blood GSH levels were significantly lower in patients with PDR compared to those with PVR (p < 0.0001 for both). CONCLUSION: Elevated levels of vitreous and plasma NO and vitreous IL-8 in PDR and PVR implicate a role for these parameters in the proliferation in these ocular disorders. GSH concentrations both in vitreous and blood samples of the PVR and PDR patients were much less than those observed in the control group. Lower GSH concentrations detected in PDR in comparison with those in PVR in vitreous humor and to a lesser degree in blood may play an important role in pathogenesis of new retinal vessel formation in patients with PDR. This also suggests that oxidative stress may be involved in the pathogenesis of PVR and particularly that of PDR.
机译:目的:评估增生性糖尿病视网膜病变(PDR)和增生性玻璃体视网膜病变(PVR)患者的玻璃体液和血液样本中的白细胞介素8(IL-8),一氧化氮(NO)和谷胱甘肽(GSH)概况,以及将水平与对照水平进行比较。患者和方法:使用血浆和玻璃体液样品中的Greiss反应测定NO浓度。使用二硫化物色原DTNB测定血液和玻璃体液样品中的GSH水平。通过ELISA测定玻璃体IL-8。本研究纳入了23例PDR患者,18例PVR患者和21具尸体作为对照组。结果:PDR患者血浆和玻璃体NO水平分别为25.6 +/- 2.1和36.9 +/- 3.0 micromol / l,PVR和17.4分别为27.0 +/- 4.7和34.3 +/- 2.9 micromol / l对照分别为+/- 2.7和15.9 +/- 1.4 micromol / l。玻璃体液和血浆NO水平在PDR和PVR组之间没有显示任何统计学上的显着差异。但是,两组的玻璃体值均明显高于对照组(p <0.0001)。尽管PDR患者玻璃样中的IL-8水平与PVR患者(42.2 +/- 7.3 pg / ml)无明显差异(79.6 +/- 9.7 pg / ml)(p = 0.06),两组均显着高于对照组(19.0 +/- 3.9 pg / ml)(分别为p <0.0001和p <0.05)。发现血液和玻璃体中的GSH水平为5.3 +/- 0.4 micromol / g。 PDR和8.4 +/- 0.5 micromol / g患者的Hb和0.58 +/- 0.16 micromol / l。 PVR和12.0 +/- 1.1 micromol / g患者的Hb和15.7 +/- 2.2 micromol / l。对照中的Hb和0.26 +/- 0.03 mmol / l。与PVR患者相比,PDR患者的玻璃体和血液GSH水平明显降低(两者均p <0.0001)。结论:PDR和PVR中玻璃体和血浆NO以及玻璃体IL-8水平升高,暗示这些参数在这些眼部疾病的增殖中起作用。 PVR和PDR患者的玻璃体和血液样本中的GSH浓度均远低于对照组。与玻璃体液中的PVR相比,PDR中检测到的GSH浓度较低,血液中的GSH浓度较低,可能在PDR患者新的视网膜血管形成的发病机理中起重要作用。这也表明氧化应激可能与PVR的发病机理有关,尤其是PDR的发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号